ERBB2 and gastric cancer: Both in-situ gastric cancer SCID mouse models and subcutaneous gastric cancer nude mouse models were employed to evaluate the efficacy, where HER2-RQDs nanoprobes were intravenously administered, and their biodistribution and therapeutic effects were quantified [212,213].